ArticleDoklady. Biochemistry and biophysics2025
Biphasic Effects of bFGF Blockade on Lung Cancer Cell Invasion.
Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basic fibroblast growth factor (bFGF) is a potent mitogen implicated in tumor progression, yet its precise role in cancer cell invasion remains multifaceted. Here, we unveiled a dose-dependent, biphasic regulatory effect of bFGF blockade on the invasiveness of lung cancer cells. Using a neutralizing monoclonal antibody against bFGF (bFGF Ab), we demonstrated that moderate neutralization of bFGF inhibited tumor cell invasion. Conversely, excessive bFGF blockade paradoxically enhanced the invasive capacity of lung cancer cells. Furthermore, we showed that the divergent invasive phenotypes arising from varying degrees of bFGF inhibition were mediated by altered vascular endothelial growth factor (VEGF) secretion. These findings underscore the critical importance of dose optimization in bFGF-targeted therapies, particularly concerning their impact on lung cancer invasiveness, and identify VEGF as a key mediator of these effects.
Indexed as
Identifiers
40947429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.